Cover Image
市場調查報告書

全球生技藥品API (原料藥) 製造服務業和市場預測 2017年∼2027年:哺乳類細胞培養·微生物發酵·人體生長荷爾蒙·胰島素·干擾素·單株抗體、疫苗

Biological Drug API Manufacturing Services World Industry and Market Predictions 2017-2027: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine

出版商 Visiongain Ltd 商品編碼 333982
出版日期 內容資訊 英文 227 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球生技藥品API (原料藥) 製造服務業和市場預測 2017年∼2027年:哺乳類細胞培養·微生物發酵·人體生長荷爾蒙·胰島素·干擾素·單株抗體、疫苗 Biological Drug API Manufacturing Services World Industry and Market Predictions 2017-2027: Mammalian Cell Culture, Microbial Fermentation, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccine
出版日期: 2017年08月01日 內容資訊: 英文 227 Pages
簡介

本報告提供全球生技藥品 (生物科技)的API (原料藥) 受託製造服務市場相關調查,彙整全球外包生技藥品API市場·子市場收益,主要國家市場分析,影響生物醫藥品API開發·製造的課題與機會,及主要企業簡介等資訊,為您概述為以下內容。

第1章 調查概要

第2章 生物科技API製造服務的概要

  • 生物科技API製造服務是什麼?
  • 生物科技API的製造相關課題
  • 外包:生物科技API製造服務的共同流程
  • 生物科技API製造服務市場未來展望

第3章 生物科技API製造服務:全球市場的展望·預測

  • 生物科技API受託製造服務市場業績 (最新值)
    • 業績預測 (今後11年份)
  • 生物科技API製造服務推動、阻礙市場要素
    • 推動市場要素
      • 人口高齡化,「專利的懸崖」,開發平台工程的長期化,技術進步等
    • 阻礙市場要素
      • 價格壓力,法規,生產能力過剩,工程的複雜
  • 生物科技API製造的外包服務的未來展望:需求擴大

第4章 生物科技API製造服務市場:各領域的展望·預測

  • 生物科技API製造服務業的子市場
    • 哺乳類細胞培養市場
    • 哺乳類細胞培養市場預測 (今後11年份)
    • 預計ADS及新一代抗體促進成長
    • 微生物發酵市場
    • 微生物發酵市場預測 (今後11年份)
    • 其他API表現系統:尚在開發中
      • 植物性醫藥品
      • 酵母細胞·昆蟲細胞等的表現系統
  • 本章的摘要:市場正成長

第5章 生物科技API製造服務市場:生技藥品API受託製造的主要部門的未來展望

  • 抗體療法:生技藥品API受託製造的最大部門 (概要)
    • 市場趨勢預測 (今後11年份),未來展望·課題
  • API疫苗受託製造:對CMO (醫藥品受託製造機關) 而言的有潛力機會
  • 胰島素治療市場概要和胰島素治療用API的受託製造市場展望
    • 胰島素類似物市場預測 (內製/外包)
  • 干擾素治療市場概要和干擾素治療用API的受託製造市場展望
  • 生長激素治療市場概要和生長激素治療用API的受託製造市場展望
  • 本章的摘要:主要的生技藥品產品的外包 (今後11年份)

第6章 主要國家的生物科技API受託製造服務市場

  • 全球生物科技API製造服務市場:各地區
    • 各地區的市場規模:趨勢預測 - 美國·歐洲主導成長
    • 各地區市場佔有率的預測值 - 新興國家的成長
  • 各地區的生物科技API受託製造的展望 (今後11年份)
    • 大幅度的市場成長預測
    • EU各國·瑞士市場預測
    • 美國市場的預測
    • 日本市場預測
    • 金磚四國市場預測
    • 韓國市場預測
    • 新加坡市場預測
  • 本章的摘要:主要國家市場預測 (今後11年份)

第7章 生物科技API製造服務市場代表性的CMO

  • 前四大公司牽引市場
  • 代表性企業:生產能力
    • 小規模的企業佔大半
    • 主要市場進入障礙
  • FDA (美國食品藥物管理局) 為生物仿製藥市場除去障礙
  • Boehringer Ingelheim BioXcellence
  • Celltrion:領導亞洲的生技藥品市場
  • DSM Biologics:生產能力的策略性擴張
  • Lonza:全球最大的細胞培養能力
  • 其他值得注意的企業
    • Fujifilm Diosynth Biotechnologies
  • 營運CMO部門的代表性生物醫藥品企業
    • AbbVie Contract Manufacturing
    • GSK Biopharmaceuticals
    • Sandoz: Expertise
    • Rentschler Biotechnologie
  • Teva:生技藥品市場的未來性企業
  • Catalent:通過事業合作,提供新的平台
  • 本章的摘要:主要企業趨勢預測 (今後11年份)

第8章 生物科技API製造服務的產業趨勢:定性分析

  • SWOT分析:優勢和弱點
  • 機會
  • 威脅
  • STEP分析 (社會·技術性·經濟·政治要素)
  • 生技藥品的開發趨勢 (今後11年份)
    • 生物相似藥:對CMO而言重要的市場機會
    • 下一代型抗體的開發投資的CMO
    • 孤兒藥·個人化醫療:貼片的小型化趨勢
    • 拋棄式型 (一次性使用) API產品的市場未來展望
    • 外包 (外包化)的趨勢預測
      • 生物醫藥品企業,公司內部的製造設備的投資也繼續
      • 新興國家市場的離岸外包生產:是否已退流行?
      • 生產能力過剩:對生物科技CMO的產業而言的威脅
      • 替代性的表現系統
  • 生物科技API製造服務市場的法規和其影響
  • 本章的摘要:生物科技API受託製造服務業的今後趨勢

第9章 結論

  • 生物科技API受託製造服務
  • 生物科技API製造服務市場未來展望
  • 市場成長的預測 (今後11年份)

第10章 用語一覽,附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0219

The Biological Drug API Manufacturing Services World Industry and Market Predictions 2017-2027: Analysis and Forecasts for Mammalian Cell Cultures, Microbial Fermentations, Other Expression Systems, Human Growth Hormones, Insulin, Interferons, Monoclonal Antibodies, Vaccines and Geography report reviews the contract active pharmaceutical ingredient (API) manufacturing market for biologics. This study gives quantitative and qualitative analysis for that overall world market, as well as for countries and other submarkets, including the mammalian cell culture and microbial fermentation segments. This report assesses leading applications and significant developments within each, as well as drivers and restraints for them. Future trends that will affect the biotech API manufacturing services market are also examined. In addition, this study profiles leading contract manufacturing organisations (CMOs) in the outsourcing market and assesses their outlooks. Visiongain provides forecasts revenues for the period 2016 to 2027 for the biotech API manufacturing services market, as well as for therapeutic applications.

How this 227 page report delivers:

  • Provides qualitative and quantitative analysis of the leading submarkets the period 2017-2027. Visiongain forecasts revenues and their growth for these submarkets:
    • Mammalian cell culture
    • Microbial fermentation
    • Other expression platforms
  • Provides qualitative and quantitative analysis of the leading contract API biological drug applications for the period 2017-2027. Visiongain forecasts contract API drug revenues to 2027 for these individual segments:
    • Monoclonal antibody (mAb) therapies
    • Vaccines
    • Insulin therapies
    • Interferon therapies
    • Growth hormones.

image1

  • Find forecasts of the leading therapeutic and national markets from 2016 to 2027:
    • The EU, including the five leading markets (UK, Germany, France, Italy and Spain).
    • The US
    • Japan
    • Switzerland
    • Emerging markets such as the BRIC (Brazil, Russia, India, and China) countries, South Korea and Singapore.
  • Profiles leading global and national companies that offer biotech API manufacturing services to the pharmaceutical industry. For each company, current services offered, recent developments and outlooks are discussed. Leading CMOs profiled in this chapter are:
    • Boehringer Ingelheim BioXcellence
    • Celltrion
    • DSM Biologics
    • Lonza
    • Samsung BioLogics
    • Cytovance Biologics
    • Fujifilm Diosynth Biotechnologies
    • Operations of leading biopharma companies, such as AbbVie, GSK and Novartis.
  • Discover the regulatory outlook for biotech API manufacturing in leading regional and national markets in 2017, as well as predicted developments for the period to 2027.
  • Identify important drug development and technology trends that will affect CMOs, their clients and other market participants from 2017. The report also contains SWOT and STEP analysis of the industry and market.
  • Find profiles for leading CMOs offering biological drug API manufacturing services to pharmaceutical companies.

Table of Contents

1. Report Overview

  • 1.1 Contract Biotech API Manufacturing: World Market Review 2017
  • 1.2 Benefits of this Report
    • 1.2.1 How This Report Delivers
    • 1.2.2 Main Questions Answered by This Analytical Report
  • 1.3 Who is This Report For?
  • 1.4 Methods of the Study
  • 1.5 Frequently Asked Questions (FAQ)
  • 1.6 Some Associated Reports
  • 1.7 About Visiongain

2. Introduction to Biotech API Manufacturing Services

  • 2.1 What are Biotech API Manufacturing Services?
    • 2.1.1 Producing Biotech API: An Overview of the Manufacturing Process
    • 2.1.2 Defining the Biotech API Manufacturing Market
    • 2.1.2 Differing Expression Systems to Manufacture APIs
  • 2.2 Challenges in Manufacturing Biotech API
  • 2.3 Outsourcing: A Common Trend in Biotech API Manufacturing Services
  • 2.4 Future Trends for the Biotech API Manufacturing Services Market

3. Biotech API Manufacturing Services: World Market Outlook and Forecast 2017-2027

  • 3.1 The Contract Biotech API Manufacturing Services Market Performance, 2016
    • 3.1.1 Contract Biotech API Manufacturing Services: Forecast 2017-2027
  • 3.2 Drivers and Restraints in the Biotech API Manufacturing Services Market
    • 3.2.1.1 The Ageing Population is a Driver for Growth
    • 3.2.1.2 The Patent Cliff Effect Will Stimulate Biologics and Biosimilar Development
    • 3.2.1.3 Outsourcing as a Driver for Growth
    • 3.2.1.4 Opportunities from the Long Pipeline Will Drive Growth
    • 3.2.1.5 Increased Investment in Orphan Drugs from Companies
    • 3.2.1.6 Emerging Markets Will Grow and Influence the Market
    • 3.2.1.7 Technological Changes: Single-Use Technology Will Become Essential in the Next 10 Years
    • 3.2.2 Restraints on Growth in the Biotech API Manufacturing Services Market
    • 3.2.2.1 Pricing Pressures Will Limit Market Growth
    • 3.2.2.2 Regulatory Restrictions Will Increase
    • 3.2.2.3 Overcapacity Will Be Adverse to Market Growth for CMOs
    • 3.2.2.4 Complexity of API Production is a Challenge
  • 3.3 Outlook for the Outsourced Biotech API Services: Increased Demand

4. Biotech API Manufacturing Services Submarkets: World Market Outlook and Forecasts 2017-2027

  • 4.1 Submarkets for the Biotech API Manufacturing Services Industry
    • 4.1.1 The Mammalian Cell Culture Submarket
    • 4.1.2 The Mammalian Cell Culture Submarket Forecast 2017-2027
    • 4.1.3 ADCs and Next-Generation Antibodies Will Drive Growth 2017-2027
    • 4.1.4 The Microbial Fermentation Submarket
    • 4.1.5 The Microbial Fermentation Submarket Forecast 2017-2027
      • 4.1.5.1 Increase in Demand for Insulin Will Drive Growth 2017-2027
    • 4.1.6 Other APIs Expression Systems Are Still in Development
      • 4.1.6.1 Plant-Made Pharmaceuticals
      • 4.1.6.2 Yeast Cell Expression Systems
      • 4.1.6.3 Insect Cell Expression Systems
      • 4.1.6.4 Other Expression Systems Submarket Forecast 2017-2027
  • 4.2 Chapter Summary: Positive Growth for the Market

5. Biotech API Manufacturing: Outlook for Leading Biological Drug Contract API Sectors: 2017-2027

  • 5.1 Antibody Therapies: An Introduction to the Largest Contract API Biological Drug Sector
    • 5.1.1 Contract API Monoclonal Antibody Manufacturing Forecast 2017-2027
    • 5.1.2 Outlook: Outsourced Manufacturing for Monoclonal Antibody APIs Will Increase
  • 5.2 Contract API Vaccine Manufacturing: A Promising Opportunity for CMOs
    • 5.2.1 Contract API Vaccine Market: Outlook and Forecast 2017-2027
    • 5.2.2 Challenges in Manufacturing Vaccines
  • 5.3 Introduction to the Insulin Therapies Market and Outlook for the Contract API Insulin Therapies Market
    • 5.3.1 Contract API Insulin Analogues Forecast 2017-2027
    • 5.3.2 Insulin Analogues: In-House Production Restrains Contract API Insulin Therapies Market Growth
    • 5.3.3 Development Trends in the Contract API Insulin Market to 2027
  • 5.4 Introduction to the Interferon Therapy Market and Outlook for the Contract API Interferon Therapy Market
    • 5.4.1 Contract API Interferon Market Forecast 2017-2027
    • 5.4.2 Unlikely to be Opportunities in the Contract API Interferon Market
  • 5.5 Introduction to the Growth Hormone Market and Outlook for the Contract API Growth Hormone Manufacturing Market
    • 5.5.1 Contract API Growth Hormone Market Forecast 2016 to 2027
    • 5.5.2 Most Manufacturing is In-House for Growth Hormone Production
    • 5.5.3 Long-Acting Therapies Provide Opportunity for Outsourcing
  • 5.6 Chapter Summary: Outsourcing for Key Biological Products 2017-2027

6. Leading National Markets for Contract Biotech API Manufacturing Services 2017-2027

  • 6.1 Regional Breakdown of the World Biotech API Manufacturing Services Market
    • 6.1.1 US and EU Dominate Growth for Leading National Submarkets 2017-2027
    • 6.1.2 National Revenue Shares by 2027: Emerging Market Growth
  • 6.2 Contract Biotech API Manufacturing in EU Market 2017-2027
    • 6.2.1 Strong Growth for the EU Revenue Forecasts 2017-2027
    • 6.2.2 Forecasts for Switzerland and Leading EU National Revenues 2017-2027
      • 6.2.2.1 Germany Leads the EU Biotech Market with Strong Growth
      • 6.2.2.2 UK: Strong Research Sector Will Drive Market Growth
      • 6.2.2.3 France: Strong Vaccine Development Industry
      • 6.2.2.4 Switzerland: Headquarters for Leading Companies
      • 6.2.2.5 Spain: Numerous Biotech Companies
      • 6.2.2.6 Italy: Outlook and Forecast 2017-2027
    • 6.2.3 US: A Market Leader in Biotech API Manufacturing
    • 6.2.4 Japan: A Less Mature Contract Manufacturing Market
    • 6.2.5 BRIC Market: Outlook and Forecasts for Emerging Markets 2016- 2027
      • 6.2.5.1 Emerging Nations May Develop a Presence in the Biologics Market
      • 6.2.5.2 Increased Demand for Biosimilars and Biological Drugs 2017-2027
      • 6.2.5.3 China is Poised for Growth: Forecast for 2017-2027
      • 6.2.5.4 India Offers a Lower-Cost Advantage for Biotech API Manufacturing Services: Forecast 2017-2027
      • 6.2.5.5 Brazilian and Russian Governments Promoting Domestic Biotech Development
      • 6.2.5.6 Russian Biotech API Manufacturing Services Forecast: 2017-2027
      • 6.2.5.7 Brazilian Biotech API Manufacturing Services Forecast: 2017-2027
    • 6.2.6 South Korea: Market Forecast, 2017-2027
      • 6.2.6.1 Leading CMOs Celltrion and Samsung BioLogics Drive the Market
    • 6.2.7 Singapore: Market Forecast, 2017-2027
  • 6.3 Summary of Chapter: Outlook for Leading National Submarkets 2017-2027

7. Leading CMOs in the Biotech API Manufacturing Services Market 2016

  • 7.1 Four Companies Led the Market in 2016
  • 7.2 Leading Companies by Capacity
    • 7.2.1 Small-Scale Biopharmaceutical Manufacturing is a Common Trend
    • 7.2.2 Barriers to Market Entry 2017-2027
    • 7.2.2.1 The High Cost of Facilities: Acquisition as a Cheaper Alternative
  • 7.3 FDA Opens Barriers for the Biosimilars Market
  • 7.4 Boehringer Ingelheim BioXcellence
    • 7.4.1 Strategic Outlook: Expanding into the Asian Market
  • 7.5 Celltrion: Biologics Leader in Asia
    • 7.5.1 Celltrion: Likely Target for Mergers and Acquisitions?
  • 7.6 DSM Biologics: Strategically Increasing Capacity
  • 7.7 Lonza Has the Largest Worldwide Cell Culture Capacity
    • 7.7.1 Lonza: Biopharmaceutical Core Competency as a Strategy for Growth
  • 7.8 Other Market Players of Interest in 2016
    • 7.8.1 Samsung BioLogics: Focusing on Biosimilars
    • 7.8.2 Cytovance Biologics: Plans to Expand
    • 7.8.3 Fujifilm Diosynth Biotechnologies
    • 7.8.3.1 Facility and Service Expansion for the Future
  • 7.9 Leading Biopharma Companies Operate CMO Divisions
    • 7.9.1 AbbVie Contract Manufacturing: Strength through Acquisition
    • 7.9.2 GSK Biopharmaceuticals
    • 7.9.3 Sandoz: Expertise in Biologics and Biosimilars
    • 7.9.4 Rentschler Biotechnologie: Recent Expansions
  • 7.10 Teva: A Future Player in the Biologics Market
  • 7.11 Catalent Offers a New Platform through Partnership
  • 7.12 Chapter Summary: Leading Companies 2016-2027

8. Biotech API Manufacturing Services Market Industry Trends 2017-2027: Qualitative Analysis

  • 8.1 SWOT Analysis: Strengths and Weaknesses of the Biotech API Manufacturing Services Market 2017
    • 8.1.1 Biopharmaceutical Demand for Outsourcing is Increasing
    • 8.1.2 A Fragmented Market with a Costly and Difficult Manufacturing Process
  • 8.2 Opportunities for the Biotech API Manufacturing Services Market 2017-2027
  • 8.3 Threats for the Biotech API Manufacturing Services Market 2017-2027
  • 8.4 STEP Analysis of the Biotech API Manufacturing Services Market
    • 8.4.1 Social Factors: Drug Pricing Pressures to Meet Demand for an Increasing Ageing Population
    • 8.4.2 Technological Factors: Advances Will Drive Growth
      • 8.4.2.1 Single-Use Technology: A Vital Trend for the Future
    • 8.4.3 Economic Factors: The High Cost of Manufacturing Will Lead to Outsourcing
    • 8.4.4 Political Factors: Regulatory Requirements Need to Be Met
  • 8.5 Trends in Biological Drug Development 2017-2027
    • 8.5.1 Biosimilars Will Be an Important Opportunity for CMOs
    • 8.5.2 CMOs are Investing in Next-Generation Antibody Development
    • 8.5.3 Orphan Drugs and Personalised Medicine: Trend for Smaller Batches
    • 8.5.4 Outlook for Single-Use Technologies in Biotech API Manufacturing 2017-2027
    • 8.5.5 Outsourcing Trends for Biotech API Manufacturing 2017-2027
      • 8.5.5.1 Biopharma Companies Continue to Invest in In-House Facilities
      • 8.5.5.2 Off-shoring Biotech API Manufacturing to Emerging Markets: Not a Trend for this Decade?
      • 8.5.5.3 Overcapacity is a Risk for the Biotech CMO Industry
      • 8.5.5.4 Future Trends: Strategic Partnering
      • 8.5.5.5 Alternative Expression Methods
  • 8.6 Regulations and Effects on the Biotech API Manufacturing Services Industry
    • 8.6.1 Effect on the Emerging Biotech API Manufacturing Services Market 2017-2027
    • 8.6.2 Regulations in Other Countries in the Biotech API Market
  • 8.7 Chapter Summary: Industry Trends for Contract Biotech API Manufacturing to 2027

9. Conclusions

  • 9.1 The Contract Biotech API Manufacturing Services Market
  • 9.2 Outlook for the Biotech API Manufacturing Services Market
    • 9.2.1 Mammalian Cell Culture is the Leading Expression Platform for Outsourced Biotech API Manufacturing
    • 9.2.2 The US and EU Markets Lead for the Global Biotech API Manufacturing Services Market in 2016
    • 9.2.3 Single-Use Technology Will Become Indispensable for Success in the Market
  • 9.3 Growth in the Market 2017-2027
    • 9.3.1 The Future of the Biotech API Manufacturing Services Marketplace

10. Glossary

  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • Appendix A
  • About Visiongain
  • Appendix B

List of Figures

  • Figure 1.1 Biological Drug API Manufacturing Services Submarkets 2017
  • Figure 2.1 Steps for Biological Drug Manufacturing, 2017
  • Figure 2.2 Contract API Manufacturing: Market Shares by Sector (%), 2016
  • Figure 2.3 Future Trends in the Biotech API Manufacturing Market, 2017-2027
  • Figure 3.1 Contract Biotech API Manufacturing Services Market: Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 3.2 Contract Biotech API Manufacturing: Market Drivers, 2017-2027
  • Figure 3.3 Contract Biotech API Manufacturing: Market Restraints, 2017-2027
  • Figure 4.1 Contract Biotech API Manufacturing: Market Shares (%) by Sector, 2016
  • Figure 4.2 Mammalian Cell Culture Submarket Forecast, Revenue ($bn), AGR(%), 2017-2027
  • Figure 4.3 Mammalian Cell Culture Submarket: Drivers and Restraints, 2017-2027
  • Figure 4.4 Microbial Fermentation Submarket Forecast($bn), AGR (%), 2017-2027
  • Figure 4.5 Microbial Fermentation Submarket: Drivers and Restraints, 2016
  • Figure 4.9 Forecast for Other Expression Systems Submarket Forecast ($bn), AGR (%), CAGR (%), 2016-2021
  • Figure 4.10 Forecast for Other Expression Systems Submarket Forecast ($bn), AGR (%), CAGR (%), 2022-2027
  • Figure 5.1 Leading Contract API Biological Drug by Sector, 2016
  • Figure 5.2 Monoclonal Antibody Market: Contract API Revenues Forecast ($bn), AGR (%), 2017-2027
  • Figure 5.3 Vaccines Market: Contract API Revenues Forecast ($bn), AGR(%) 2017-2027
  • Figure 5.4 Comparison between biomanufacturing platforms for Vaccine production: VLP
  • Figure 5.5 Insulin Therapies Market: Contract API Revenues Forecast ($bn), AGR (%), 2017-2027
  • Figure 5.6 Interferon Therapies Market: Contract API Revenues Forecast ($bn), AGR (%), 2017-2027
  • Figure 5.7 Growth Hormones Market: Contract API Revenues Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.1 Contract Biotech API Manufacturing: Market Shares by Region (%), 2016
  • Figure 6.2 Contract Biotech API Manufacturing: Market Shares by Region (%) 2020
  • Figure 6.3 Contract Biotech API Manufacturing: Market Shares by Region (%) 2026
  • Figure 6.4 EU and Switzerland Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.5 EU Contract Biotech API Manufacturing: Leading National Revenue Shares (%), 2016
  • Figure 6.6 Germany Contract Biotech API Manufacturing Revenue Forecast ($bn), 2017-2027
  • Figure 6.7 UK Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.8 France Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.9 Switzerland Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.10 Spanish Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.11 Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.12 US Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.13 Japanese Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.14 Contract Biotech API Manufacturing Market: BRIC National Revenue Forecasts ($bn), AGR (%), 2016 -2027
  • Figure 6.15 Biologics Market: BRIC Revenue Shares (%), 2016
  • Figure 6.16 Chinese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2017-2027
  • Figure 6.17 India Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.18 Russia Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.19 Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.20 South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 6.21 Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), AGR (%), 2017-2027
  • Figure 7.1 Leading Biotech API CMOs: Mammalian Cell Culture Manufacturing Scale, 2016
  • Figure 7.2 Leading Biotech API CMOs: Microbial Fermentation Manufacturing Scale, 2015
  • Figure 7.3 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2014-2016
  • Figure 7.4 Celltrion: Revenue ($bn), 2009-2015
  • Figure 7.5 DSP: Pharmaceutical Biotech Manufacturing Revenue ($bn), 2011-2015
  • Figure 7.6 Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), 2012-2016
  • Figure 9.1 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2016 - 2027
  • Figure 9.2 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2016, 2018, 2020, 2022, 2024 and 2026

List of Tables

  • Table 1.1: Redacted Submarket Forecast : Revenue Forecasts by Sector ($bn), Annual Growth (%) and CAGR, 2017-2027
  • Table 2.1 Contract API Manufacturing: Revenues ($bn) and Market Share (%) by Sector, 2016
  • Table 3.1 Contract Biotech API Manufacturing Services Market: Overall Revenue Forecast ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 3.2 Contract Biotech API Manufacturing Services Market: Overall Revenue Forecast ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 4.1 Contract Biotech API Manufacturing: Overall World Market and Main Submarket Revenue Forecasts ($bn), AGR(%), CAGR(%), 2016-2021
  • Table 4.2 Contract Biotech API Manufacturing: Overall World Market and Main Submarket Revenue Forecasts ($bn), AGR(%), CAGR(%), 2022-2027
  • Table 4.3 ADC Pipeline 2016
  • Table 4.3 ADC Pipeline 2016 (continued)
  • Table 4.3 ADC Pipeline 2016 (continued)
  • Table 4.4 Mammalian Cell Culture Submarket: API Revenue Forecast ($bn), AGR(%), CAGR(%), 2016-2021
  • Table 4.5 Mammalian Cell Culture Submarket: API Revenue Forecast ($bn), AGR(%), CAGR(%), 2022-2027
  • Table 4.6 Other Expression Systems Submarket Two Year Forecast Revenues ($bn), AGR (%), 2017-2027
  • Table 4.6 Selected CMOs Investing in Biological API Manufacturing Capacity, 2016
  • Table 4.7 Microbial Fermentation: API Submarket Revenue Forecast ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 4.8 Microbial Fermentation: API Submarket Revenue Forecast ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 5.1 Top Ten Best-Selling Drugs in 2016: Revenue ($bn)
  • Table 5.2 Contract API Biological Drug Revenue Forecasts ($bn), AGR (%), CAGR (%), by Therapeutic Area, 2016-2021
  • Table 5.3 Leading Contract API Biological Drug Revenue Forecasts ($bn) AGR (%), CAGR (%), by Therapeutic Area, 2022-2027
  • Table 5.4 Monoclonal Antibody Types and Sources
  • Table 5.5 Monoclonal Antibody Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 5.6 Monoclonal Antibody Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 5.7 The Four Classes of Next- Generation Antibody Therapies
  • Table 5.8 Vaccines Market: Contract API Revenue Forecast ($bn), GAGR (%), AGR (%) 2016-2021
  • Table 5.9 Vaccines Market: Contract API Revenue Forecast ($bn), GAGR (%), AGR (%) 2022-2027
  • Table 5.10 Insulin Therapies Market: Contract API Revenue Forecast ($bn), AGR (%), CAGR (%), 2016-2021
  • Table 5.11 Insulin Therapies Market: Contract API Revenue Forecast ($bn), AGR (%), CAGR (%), 2022-2027
  • Table 5.12 Interferon Therapies Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 5.13 Interferon Therapies Market: Contract API Revenue Forecast ($bn), ), CAGR (%), AGR (%), 2022-2027
  • Table 5.14 Growth Hormones Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 5.15 Growth Hormones Market: Contract API Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 5.16 Selected Long-Acting Growth Hormones in Development, 2016
  • Table 6.1 Contract Biotech API Manufacturing Market: Revenues ($bn) and Market Shares (%) by Region, 2016
  • Table 6.2 Contract Biotech API Manufacturing Market: Leading Regional and National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.3 Contract Biotech API Manufacturing Market: Leading Regional and National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.4 Contract Biotech API Manufacturing Market: National Revenue Two Year Shares (%), 2016-2026
  • Table 6.5 EU and Switzerland Contract Biotech API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2016-2021
  • Table 6.6 EU and Switzerland Contract Biotech API Manufacturing: Revenue Forecasts ($bn), GAGR (%), AGR (%), 2021-2026
  • Table 6.7 EU and Switzerland Contract Biotech API Manufacturing: Revenues ($bn) and Shares (%) by Leading Country, 2016
  • Table 6.8 Germany Contract Biotech API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%), 2016-2021
  • Table 6.9 Germany Contract Biotech API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%), 2022-2027
  • Table 6.10 UK Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2016-2021
  • Table 6.11 UK Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2022-2027
  • Table 6.12 France Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2016-2021
  • Table 6.13 France Contract Biotech API Manufacturing Revenue Forecast ($bn), GARG (%), AGR (%), 2022-2027
  • Table 6.14 Switzerland Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.15 Switzerland Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.16 Spain Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%),2016-2021
  • Table 6.17 Spain Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.18 Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.19 Italian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.20 US Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.21 US Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.22 Japanese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.23 Japanese Contract Biotech API Manufacturing Revenue Forecast, CAGR (%), AGR (%), ($bn),2022-2027
  • Table 6.24 Contract Biotech API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.25 Contract Biotech API Manufacturing Market: BRIC National Revenue Forecasts ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.26 BRIC Markets: API Revenues ($bn) and Market Shares (%), 2016
  • Table 6.27 Chinese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.28 Chinese Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.29 India Contract Biotech API Manufacturing Revenue Forecast ($bn), GAGR (%), AGR (%) 2016-2021
  • Table 6.30 India Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.31 Russia Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.32 Russia Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.33 Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.34 Brazilian Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.35 South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.36 South Korean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 6.37 Selected Biotechs and Pharmaceutical Companies with Manufacturing Facilities in Tuas, 2015
  • Table 6.38 Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2016-2021
  • Table 6.39 Singaporean Contract Biotech API Manufacturing Revenue Forecast ($bn), CAGR (%), AGR (%), 2022-2027
  • Table 7.1 Leading Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2015
  • Table 7.2 Selected Other Biotech API CMOs: Mammalian Cell Culture and Microbial Fermentation Manufacturing Scale, 2015
  • Table 7.3 Boehringer Ingelheim BioXcellence: Manufacturing Capacity, 2015
  • Table 7.4 Boehringer Ingelheim BioXcellence: Revenue ($bn), 2014-2016
  • Table 7.5 Celltrion: Revenue ($bn), CAGR (%), AGR (%), 2009-2015
  • Table 7.6 Lonza: Pharmaceutical Contract Manufacturing Revenue ($bn), CAGR (%), AGR (%), 2012-2016
  • Table 7.7 Lonza: New Biological Drug Sector Manufacturing Agreements, 2015
  • Table 7.8 Sandoz Biosimilar Pipelines: Selected Biosimilars, 2016
  • Table 8.1 Contract Biotech API Manufacturing Market: Strengths and Weaknesses, 2016-2017
  • Table 8.2 Contract Biotech API Manufacturing Market: Opportunities and Threats, 2017-2027
  • Table 8.3 Biotech API Manufacturing Services Market: STEP Analysis, 2017
  • Table 8.4 Selected EU-Approved Biosimilars: Manufacturers and Companies, 2016
  • Table 8.5 Approved Next-Generation Antibody Therapies, 2016
  • Table 9.1 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Sector, 2016, 2018, 2020, 2022, 2024 and 2026
  • Table 9.2 Contract Biotech API Manufacturing Market: Revenue Forecasts ($bn) by Region, 2016, 2018, 2020, 2022, 2024 and 2026

Companies Listed

  • Abasria
  • AbbVie
  • Accord Healthcare
  • Acquired Cedarburg Pharmaceuticals,
  • Actavis Generics
  • Adaptimmune Therapeutics
  • Agensys
  • Althera Technologies
  • Altus Pharmaceuticals
  • Amgen
  • Apotex
  • Aptuit
  • arGEN-X
  • Ascendis Pharma A/S
  • Asterion
  • Astra Zeneca
  • Avid Bioservices Inc
  • Bakhu Pharma.
  • Banner Life Sciences
  • Basaglar
  • Baxalta
  • Baxter
  • Bayer
  • Bever Pharmaceutical
  • Biocad
  • Biocon
  • Biogen
  • Biogen Idec
  • BMS
  • Boehringer Ingelheim
  • Boehringer Ingelheim BioXcellence
  • Bolder BioTechnology
  • Calico Life Science
  • Caspugel
  • Catalent Biologics
  • Celgene
  • Celldex Therapautics
  • Celltrion
  • Cinfa
  • CMC Biologics
  • CMIC Holdings Co. Ltd.
  • CMO Relthy Laboratórios
  • Cook Pharmica
  • Critical Pharmaceuticals
  • CT Arzneimittel
  • Cytos Biotechnology
  • Cytovance Biologics
  • DPx Fine Chemicals
  • DPx Holdings B.V.
  • DSM Biologics
  • DSM Sinochem Pharmaceuticals
  • Eli Lily
  • EMD Millipore
  • EMD Millipore
  • Ferring Pharmaceuticals
  • Filnox Biotech
  • Fresenius
  • Fujifilm Diosynth Biotechnologies
  • Gallus BioPharmaceuticals,
  • GE Healthcare
  • Genentech
  • GeneScience Pharmaceuticals Co., Ltd.
  • Genexine and Handok
  • Genmab
  • Genzyme
  • Gilead Sciences, Inc.
  • GSK
  • Hanmi Pharmaceutical Co.
  • Hexal
  • Index Ventures
  • Infarco
  • Infinity Pharmaceuticals
  • Inno Biologics
  • Innovation Network Corporation of Japan (INCJ),
  • Johnson and Johnson
  • Johnson Matthey
  • JSR Corporation
  • Kalon Bio
  • Kalon Bio therapeutics
  • KBI Biopharma, Inc.
  • Kemwell
  • Kyowa Hakko Kirin
  • Labrys Biologics Inc,
  • Laureate Biopharma
  • LG Life Sciences, Ltd.
  • Lonza
  • Matrix Laboratories
  • Merck
  • Mitsubishi Gas Chemical Company
  • Mylan
  • Neopharm
  • Nikon
  • Nippon kayaku
  • Norbitec
  • Novartis
  • Novasep
  • Novo Nordisk
  • Nuron Biotech
  • Nycomed
  • OPKO Biologics and Pfizer
  • Opko Health
  • Patheon
  • PelChem
  • Peregrine Pharmaceuticals
  • Perrigo
  • Pfizer
  • Pharmstandard
  • Phyton Biotech
  • Piramal Healthcare
  • Precision Biologics
  • Progenics
  • Quintiles
  • Rebtschler Biotechnologie
  • Recepta Biopharma
  • Redwood Bioscience
  • Rentschler
  • Rentschler Biotechnologie
  • Roche
  • RoYal DSM
  • SAFC
  • Samsung BioLogics
  • Sanofi
  • SCM Pharma
  • Seattle Genetics
  • ShangPharma
  • SICOR Biotech
  • Sigma-Aldrich Corporation
  • Stada
  • SunShine Biopharma
  • SynCo BioPartners
  • Takeda
  • Teva
  • Therapure Biopharma
  • Thermo Fisher
  • Toyobo Biologics
  • Transgene SA
  • Versartis
  • Vertex
  • Vida Pharma
  • VTU
  • WuXi Biologics,
  • WuXi PharmaTech
  • Zhangjiang Biotech
  • Zhejiang Jiang Yuan Tang Biotechnology
  • ZJ Base

List of Organisations

  • FDA
  • Germany's Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
  • Japanese Ministry of Health, Labour and Welfare
  • NHS
  • NICE
  • WHO
Back to Top